Evoke Pharma, Inc.

Rubicon Research Private Limited

Ezra Pharma LLC

Shirish A Shah

David A Gonyer

Matthew J D'Onofrio

Stuart J Madden

Joseph A Fix

Pratibha Sudhir Pilgaonkar

Anilkumar Surendrakumar Gandhi

Matthew J D'ONOFRIO

Nasal formulations of metoclopramide, which remain stable and/or colorless upon storage over a period of time, are provided. Also provided are methods of treating disorders treatable with metoclopramide, comprising administering the nasal solutions to patients in need thereof.

Nasal formulations of metoclopramide

The present invention provides extended release pharmaceutical formulations of valsartan with controlled impurity levels. Particularly, the present invention provides extended release valsartan formulation which is substantially free of valsartan R-isomer impurity.

Extended release pharmaceutical formulations with controlled impurity levels

The present invention relates to coated extended release pharmaceutical formulations of valsartan comprising a core comprising valsartan and at least one coating layer over the core. The present invention further relates to extended release pharmaceutical formulations comprising (a) a core comprising valsartan and at least one hydrophilic swelling polymer and (b) at least one coating layer over the core wherein the coating layer in contact with the core is applied from an organic solvent based system.

Extended release pharmaceutical formulations

Growing community of inventors

Phoenix, AZ, United States of America

Shirish A Shah